AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 171 min read$ADPT

BOBULSKY SUSAN sold $32K of ADPT

BOBULSKY SUSAN (Chief Commercial Officer, MRD) sold 1,195 shares of Adaptive Biotechnologies Corp (ADPT) at $27.00 on 2026-09-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · BOBULSKY SUSAN
Published Sep 17, 2026, 10:50 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 17, 2026, 10:53 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ADPT
Neutral
high confidence
Mentioned
$ADPT
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ADPTNeutralLow
01

Why it matters

The sale is modest and pre‑arranged, suggesting no immediate market impact.

02

Market read

Routine insider sale with limited trading relevance.

03

What to watch

Potential upcoming regulatory or clinical trial news not disclosed in the filing.

Relevance 2/10Novelty 3/10Timing: filed Sep 17 2026 (post‑market)

Background

Form 4 filing reports insider transactions required by SEC; provides transparency on officer holdings.

Company-level read

Ticker impact

$ADPTNeutralHigh confidence
Context

Chief Commercial Officer sold 1,195 shares for $32,265 via a 10b5-1 plan on Sep 15, 2026

Expected impact

minimal impact; price likely unchanged

Evidence & confidence

The transaction amount is small relative to total holdings and market cap; such sales are routine and rarely affect price.

Market effects

Sector

None; insider sale does not affect biotech sector outlook.

Regional

None; limited to Adaptive Biotechnologies shareholders.

Global

None; isolated event.

Counterpoint

What could challenge this read

If the insider is reducing exposure, it could signal concerns about near‑term prospects.

Key entities

  • Company
    Adaptive Biotechnologies Corp

    US‑listed biotech firm (ticker ADPT).

  • Insider
    Susan Bobulsky

    Chief Commercial Officer, MRD at Adaptive Biotechnologies.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ADPT insider trading history →

Related articles

JUL 29
$ADPTMed

Adaptive Biotechnologies Corp (ADPT): Results of Operations and Financial Condition

Adaptive Biotechnologies Corp (ADPT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Adaptive Biotechnologies Reports Second Quarter 2026 Financial Results SEATTLE, Jul. 29, 2026 (GLOBE NEWSWIRE) – Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the gene

SEC EDGAR 8-K6 min
JUN 5
$ADPTMedAI 9/10

Adaptive Biotech (ADPT) Reports 35% Revenue Growth Driven by Strong clonoSEQ Performance in Q1 2026

Adaptive Biotechnologies (NASDAQ:ADPT) reported Q1 2026 revenue of $70.9 million, up 35% year over year, driven by its MRD business, which generated 95% of revenue and rose 53%. clonoSEQ test volume increased 41% to 32,595. Net loss narrowed to $20.0 million; non-GAAP Adjusted EBITDA loss was $2.5 million. The company raised full-year 2026 MRD revenue guidance to $260–$270 million.

finance.yahoo.com4 min